Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I randomized, double-blind, placebo-controlled, single and multiple ascending dose study to of oral NMD1343 in healthy male and female volunteers

Next Previous
Trial Profile

A Phase I randomized, double-blind, placebo-controlled, single and multiple ascending dose study to of oral NMD1343 in healthy male and female volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NMD 1343 (Primary)
  • Indications Neuromuscular disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors NMD Pharma

Most Recent Events

  • 25 May 2023 New trial record
  • 23 May 2023 According to a NMD Pharma media release, the study was reviewed and approved by the Medicines & Healthcare products Regulatory Agency (MHRA).
  • 23 May 2023 According to a NMD Pharma media release, the first healthy volunteers have been dosed at the study site in London, UK.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top